Enavogliflozin
Clinical data
Other namesDWP16001
ATC code
  • None
Legal status
Legal status
  • Investigational
Identifiers
  • (2S,3R,4R,5S,6R)-2-[7-Chloro-6-[(4-cyclopropylphenyl)methyl]-2,3-dihydro-1-benzofuran-4-yl]-6-(hydroxymethyl)oxane-3,4,5-triol
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC24H27ClO6
Molar mass446.92 g·mol−1
3D model (JSmol)
  • C1CC1C2=CC=C(C=C2)CC3=CC(=C4CCOC4=C3Cl)[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O
  • InChI=1S/C24H27ClO6/c25-19-15(9-12-1-3-13(4-2-12)14-5-6-14)10-17(16-7-8-30-23(16)19)24-22(29)21(28)20(27)18(11-26)31-24/h1-4,10,14,18,20-22,24,26-29H,5-9,11H2/t18-,20-,21+,22-,24+/m1/s1
  • Key:KORCWPOBTZTAFI-YVTYUBGGSA-N

Enavogliflozin (DWP16001) is an experimental selective SLC5A2 and SGLT2 inhibitor developed to treat diabetes and obesity.[1][2][3][4][5]

References

  1. ↑ Hwang, Jun Gi; Lee, SeungHwan; Huh, Wan; Han, Jumi; Oh, Jaeseong; Jang, In-Jin; Yu, Kyung-Sang (September 2022). "Dose-dependent glucosuria of DWP16001, a novel selective sodium–glucose cotransporter-2 inhibitor, in healthy subjects". British Journal of Clinical Pharmacology. 88 (9): 4100–4110. doi:10.1111/bcp.15348. PMID 35395697.
  2. ↑ Kim, Ju-Hyun; Kim, Dong Kyun; Choi, Won-Gu; Ji, Hye-Young; Choi, Ji-Soo; Song, Im-Sook; Lee, Sangkyu; Lee, Hye Suk (11 September 2020). "In Vitro Metabolism of DWP16001, a Novel Sodium-Glucose Cotransporter 2 Inhibitor, in Human and Animal Hepatocytes". Pharmaceutics. 12 (9): 865. doi:10.3390/pharmaceutics12090865. PMC 7558535. PMID 32932946.
  3. ↑ Kim, Byungwook; Huh, Ki Young; Hwang, Jun Gi; Nah, JaeJin; Huh, Wan; Cho, Jae Min; Jang, In-Jin; Yu, Kyung-Sang; Kim, Yun; Lee, SeungHwan (April 2023). "Pharmacokinetic and pharmacodynamic interaction between DWP16001, an sodium–glucose cotransporter 2 inhibitor and metformin in healthy subjects". British Journal of Clinical Pharmacology. 89 (4): 1462–1470. doi:10.1111/bcp.15613. PMID 36422809. S2CID 253838705.
  4. ↑ Rhee, Beomseok; Mahbubur, Rahman Md; Jin, Changfan; Choi, Ji-Soo; Lim, Hyun-Woo; Huh, Wan; Park, Joon Seok; Han, Jumi; Kim, Sokho; Lee, Youngwon; Park, Jinho (December 2022). "Evaluation of safety and anti-obesity effects of DWP16001 in naturally obese dogs". BMC Veterinary Research. 18 (1): 237. doi:10.1186/s12917-022-03324-2. PMC 9214997. PMID 35733159.
  5. ↑ Yoon, Sukyong; Park, Min Soo; Jin, Byung Hak; Shin, Hyobin; Na, Jaejin; Huh, Wan; Kim, Choon Ok (3 July 2023). "Pharmacokinetic and pharmacodynamic interaction of DWP16001, a sodium-glucose cotransporter-2 inhibitor, with phentermine in healthy subjects". Expert Opinion on Drug Metabolism & Toxicology. 19 (7): 479–485. doi:10.1080/17425255.2023.2249397. PMID 37593838. S2CID 265846294.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.